Guides for Parents · 12 min read

ADHD Medication: What the Trials Actually Show

By Muhammad Salman Afzal, Owner & Director · Published 23 August 2026 · Updated 25 October 2026

Written by the Inclusive Developmental and Therapy Center therapy team — our Speech & Language Therapist, psychology and ABA staff. Clinical reviewer for this site: Dr Muhammad Suffyan, MB BS (GMC 8023727) · The current version of this page has not been individually signed off by our clinical reviewer.

A doctor has raised medication. Half your family says it will damage his brain, the other half says you are cruel to refuse, and everyone has an opinion delivered with total confidence.

We do not prescribe, we have no financial interest in what you decide, and this page is not advice about your child. It is the evidence, so that you walk into the appointment able to ask the right questions.

Illustration of a parent talking with a doctor about a child

The largest analysis, and what it found

A network meta-analysis in The Lancet Psychiatry pooled 133 double-blind randomised controlled trials — 81 in children and adolescents — with the efficacy analysis covering 10,068 children and adolescents. It remains the most comprehensive comparison available.

Rated by clinicians, at around 12 weeks, every drug studied beat placebo in children and adolescents:

Amphetamines: SMD −1.02 (95% CI −1.19 to −0.85)
Methylphenidate: SMD −0.78 (−0.93 to −0.62)
Atomoxetine: SMD −0.56 (−0.66 to −0.45)

Those are large effects by the standards of child mental health. Almost nothing in our own field produces numbers like that, and we are not going to pretend otherwise.

The finding almost nobody tells parents

Now the same analysis, using teachers' ratings instead of clinicians':

Only methylphenidate (SMD −0.82) and modafinil (−0.76) were more efficacious than placebo.

The results differ by who rates symptoms. This does not make one observer the only reliable judge: children face different demands at home and school, and both settings matter when reviewing treatment.

Two things follow, and they are the most useful things on this page:

It supports methylphenidate specifically. The authors' conclusion is exactly that: taking efficacy and safety together, the evidence supports methylphenidate as the preferred first choice in children and adolescents.
Review both home and school. NICE recommends recording symptoms, daily difficulties and adverse effects using parent and teacher scales before treatment and at each dose change, with regular specialist review. Agree the monitoring schedule with the prescriber.

The limitation that matters most

The same review states it plainly: there were not sufficient data for the 26-week and 52-week timepoints, and it closes by saying new research should be funded urgently to assess the long-term effects of these drugs.

So the honest summary is: good short-term evidence, thin long-term evidence. That is not a reason to refuse medication. It is a reason to treat it as a decision you keep reviewing rather than one you make once.

Side effects, in the trial data

Tolerability was measured as the proportion of patients dropping out because of side effects. In children and adolescents:

Amphetamines were less well tolerated than placebo (OR 2.30, 95% CI 1.36–3.89)
Guanfacine was less well tolerated than placebo (OR 2.64, 95% CI 1.20–5.81)
Methylphenidate and atomoxetine were not significantly worse than placebo on this measure in children — though both were in adults

In head-to-head comparisons, amphetamines were more effective than methylphenidate on clinicians' ratings. They were also the least well tolerated. That trade-off is the actual clinical decision, and it belongs to your doctor.

Growth — where the evidence genuinely disagrees

This is the fear most parents arrive with, so here are both sides rather than the one that suits an argument.

The concerning study. A nationwide cohort using Korean national health insurance records followed 34,850 young people and measured height and BMI in adulthood. Compared with people without ADHD, those with ADHD who had received methylphenidate had greater odds of a BMI in the overweight or obese range (AOR 1.60, 95% CI 1.51–1.71) and of short stature (AOR 1.08, 95% CI 1.02–1.15). The authors' own characterisation of the height finding: clinically small in both sexes, but enough to warrant regular growth monitoring.

The reassuring study. A two-year observational study with three parallel groups — medicated ADHD, unmedicated ADHD, and non-ADHD controls — compared pubertal development. The medicated and unmedicated ADHD groups did not differ in pubertal staging, so there was no sign of delayed sexual maturation with treatment. Bone age showed a slight acceleration at 24 months in the medicated subgroup, but predicted adult height remained stable. The authors concluded their results do not suggest safety concerns for growth and puberty.

What we take from the two together: the effect on final height, if there is one, is small — not the dramatic stunting families are warned about. But it is a real enough signal that height and weight should be measured at every review. If nobody is plotting your child on a growth chart, ask why.

What to ask at the appointment

"Which medicine, and why that one?" The largest analysis supports methylphenidate first in children. If something else is proposed, there may be a good reason — ask what it is.
"How will we measure whether it works?" Ask how parent and teacher observations, your child’s experience and side effects will be reviewed before treatment and during dose changes.
"What will you monitor, and how often?" Height, weight, appetite, sleep, blood pressure and pulse.
"What are the first side effects to look out for?" Appetite and sleep are the usual early ones.
"When would we reduce or stop?" A review date agreed at the start is worth more than one you have to fight for later.
"What else should we be doing alongside?" Medication does not teach a skill, and the school arrangements matter regardless.

Three things we would say plainly

Medication is not a moral failure. The effect sizes above are among the largest in child mental health. A child who has spent two years being told he is lazy and disruptive is carrying something too, and refusing on principle is a decision with its own costs.

Medication is also not a substitute for the rest. It does not teach a child how to organise a bag, start a task, or repair a friendship. It can make those things teachable, which is not the same thing.

Beware of certainty in both directions. Anyone who tells you it is poison, and anyone who tells you it is simply the answer, is going beyond the evidence in this page.

Where we fit

We do not prescribe and we will not tell you whether your child should take medication. That belongs to a doctor who has examined them.

What we do is the assessment that comes before the question — because "he cannot sit still" has more than one cause — and the work that continues whatever you decide: attention and organisation strategies, the school conversation, and the anxiety and learning difficulties that so often sit underneath. Our page on ADHD or autism covers the overlap, our ADHD page covers assessment, and autism and ADHD in girls covers the profile most often missed entirely.

If you have questions about a prescription, ask the prescribing clinician or a pharmacist. We can share observations about everyday functioning with your clinician, with your consent.

A consultation is Rs 1,500 and lasts up to 50 minutes, we work in Urdu or English, and you do not need a referral.

Sources

Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. PubMed 30097390
Song J, et al. ADHD and methylphenidate use in prepubertal children and BMI and height at adulthood. JAMA Network Open. PubMed 41490109
Carucci S, et al. The impact of methylphenidate on pubertal maturation and bone age in ADHD children and adolescents: results from the ADHD Drugs Use Chronic Effects (ADDUCE) project. Journal of Attention Disorders. PubMed 38366816
Nourredine M, et al. Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. The Lancet Psychiatry. PubMed 42134365. See the published correction to a drug label in figure 5.
NICE NG87, recommendations 1.7.26 and 1.8.3: medication monitoring and dose titration.

FAQ

Frequently asked questions

Does ADHD medication actually work?

In the short term, yes, and the effects are large by the standards of child mental health. A network meta-analysis of 133 double-blind randomised trials, with the efficacy analysis covering 10,068 children and adolescents, found every drug studied beat placebo on clinicians’ ratings at around 12 weeks — amphetamines SMD −1.02, methylphenidate −0.78, atomoxetine −0.56.

Is there a catch in that evidence?

Yes, and it is rarely mentioned. When the same trials were analysed using teachers’ ratings instead of clinicians’, only methylphenidate (SMD −0.82) and modafinil (−0.76) were more efficacious than placebo. Results differ by observer and setting. This does not make teacher reports the only reliable measure; treatment review should include both home and school.

Which medication is best for children?

The authors of that analysis concluded that, taking efficacy and safety together, the evidence supports methylphenidate as the preferred first choice in children and adolescents. Amphetamines were more effective on clinicians’ ratings but were also the least well tolerated (OR 2.30 versus placebo for dropping out due to side effects). That trade-off is a decision for your doctor.

How will I know whether it is working?

Use both parent and teacher observations. NICE recommends standard scales for symptoms, daily difficulties and adverse effects at baseline and each dose change, with regular specialist review. Agree the monitoring schedule with the prescriber and include your child’s experience.

What about long-term effects?

This is the honest weak point. The same review states there were not sufficient data for the 26-week and 52-week timepoints, and closes by calling for research into long-term effects to be funded urgently. Good short-term evidence, thin long-term evidence — which is a reason to treat medication as a decision you keep reviewing, not one you make once.

Will medication stunt my child’s growth?

The evidence genuinely disagrees, so here is both sides. A Korean national cohort of 34,850 young people found those with ADHD treated with methylphenidate had greater odds of short stature in adulthood (AOR 1.08, 95% CI 1.02–1.15) and of overweight or obesity (AOR 1.60) — with the authors calling the height difference clinically small. A separate two-year study comparing medicated ADHD, unmedicated ADHD and non-ADHD controls found no difference in pubertal staging and stable predicted adult height, and concluded there were no safety concerns for growth. These observational findings do not establish that medication caused a change in final height. Ask the prescriber how height and weight will be monitored.

What should I ask at the appointment?

Which medicine and why that one; how we will measure whether it works; what will be monitored and how often (height, weight, appetite, sleep, blood pressure, pulse); what the first side effects to watch for are; when we would reduce or stop; and what else we should be doing alongside.

Is medication enough on its own?

No. It does not teach a child how to organise a bag, start a task or repair a friendship. It can make those things teachable, which is not the same thing. Be wary of certainty in both directions — anyone telling you it is poison, and anyone telling you it is simply the answer, is going beyond the evidence.